Evelyne Silva Brum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Evelyne Silva Brum has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Sara Marchesan Oliveira
Graduate Program in Biological Sciences: Toxicological Biochemistry, Centre of Natural and Exact Sciences Federal University of Santa Maria Santa Maria Rio Grande do Sul Brazil
9 shared publications - Gabriela Becker
Center of Natural and Exact Sciences, Graduate Program in Biological Sciences: Biochemistry Toxicology, Federal University of Santa Maria, Santa Maria 97105-900, Brazil
3 shared publications - Maria Fernanda Pessano Fialho
Center of Natural and Exact Sciences, Graduate Program in Biological Sciences: Biochemistry Toxicology, Federal University of Santa Maria, Santa Maria 97105-900, Brazil
3 shared publications - Romina Nassini
Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy
3 shared publications - Camila Rodrigues Borges Linhares
Graduate Program in Odontology, Faculty of Odontology, Federal University of Uberlândia, 38400-902, Uberlândia, (MG), Brazil
2 shared publications - Cassia Regina Silva
Graduated Program in Genetics and Biochemistry, Biotechnology Institute, Federal University of Uberlândia, Uberlândia, Minas Gerais, Brazil
2 shared publications
Latest Publications
- Open Access
- 29 March 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (4) , e70424
Schwann Cell TRPA1 , a Proalgesic Ion Channel, Mediates Neuroinflammation and Fibromyalgia‐Associated Behaviours in Mice
Transient receptor potential ankyrin 1 (TRPA1) is an ion channel that integrates the somatosensory system and is specialised in detecting thermal, mechanical, and chemical stimuli. It acts as both a sensor and an amplifier of reactive oxygen and nitrogen species, carbonylic species and lipid peroxidation products, which are overproduced in several painful conditions, including fibromyalgia. Studies have linked TRPA1 to heightened sensitivity to mechanical and cold pain in fibromyalgia patients. In a preclinical mouse model of fibromyalgia induced by reserpine administration, activated Schwann cells expressing TRPA1 trigger an intracellular pathway that leads to the production of reactive oxygen species (ROS) via NADPH oxidase (NOX) 1 and to the recruitment of macrophages in the mouse sciatic and trigeminal nerves. Such mechanisms contribute to mechanical and cold hypersensitivity and early anxiety‐ and depression‐like behaviours. Future translational studies will be essential to validate whether pharmacological modulation of the Schwann cell TRPA1/NOX1 pathway could provide clinical benefit in fibromyalgia. image
- 29 March 2026
- Published by Wiley in Journal of Neurochemistry
- Vol. 170 (4) , e70424
Open AccessSchwann Cell TRPA1 , a Proalgesic Ion Channel, Mediates Neuroinflammation and Fibromyalgia‐Associated Behaviours in Mice
Transient receptor potential ankyrin 1 (TRPA1) is an ion channel that integrates the somatosensory system and is specialised in detecting thermal, mechanical, and chemical stimuli. It acts as both a sensor and an amplifier of reactive oxygen and nitrogen species, carbonylic species and lipid peroxidation products, which are overproduced in several painful conditions, including fibromyalgia. Studies have linked TRPA1 to heightened sensitivity to mechanical and cold pain in fibromyalgia patients. In a preclinical mouse model of fibromyalgia induced by reserpine administration, activated Schwann cells expressing TRPA1 trigger an intracellular pathway that leads to the production of reactive oxygen species (ROS) via NADPH oxidase (NOX) 1 and to the recruitment of macrophages in the mouse sciatic and trigeminal nerves. Such mechanisms contribute to mechanical and cold hypersensitivity and early anxiety‐ and depression‐like behaviours. Future translational studies will be essential to validate whether pharmacological modulation of the Schwann cell TRPA1/NOX1 pathway could provide clinical benefit in fibromyalgia. image
- Open Access
- 14 December 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (9) , 2009-2027
Critical role of the mast cell/tryptase/PAR2 axis in anastrozole‐induced pain
Background and Purpose: Anastrozole, an aromatase inhibitor, is used to treat postmenopausal women with hormone receptor‐positive breast cancer, but also induces musculoskeletal pain and can lead to therapeutic regimen suspension. Aromatase inhibitors promote the release of pro‐inflammatory substances from sensitised nerve fibres, which might lead to peripheral mast cell activation. Experimental Approach: We explore if tryptase released by peripheral mast cells could activate the protease‐activated receptor 2 (PAR2) to sustain anastrozole‐induced painful symptoms. Key Results: Anastrozole caused mechanical allodynia, muscle strength loss, and increased mast cell number and tryptase levels in the plantar tissue of male C57BL/6 mice. Depletion (using compound 48/80) or stabilisation (using ketotifen fumarate) of mast cells prevented anastrozole‐induced mechanical allodynia and muscle strength loss. Compound 48/80 also prevented the increase in the number of mast cells in the plantar tissue. Tryptase inhibitors nafamostat and gabexate, or PAR2 inhibitors ENMD‐1068 and AZ3451, reduced the anastrozole‐induced mechanical allodynia and muscle strength loss. Furthermore, anastrozole did not cause mechanical allodynia and muscle strength loss in global (PAR2 −/− ) or sensory neuron‐specific (PAR2 Na v 1.8 −/− ) PAR2 knockout mice. Local sub‐nociceptive doses of the PAR2 agonists (tryptase, trypsin or 2F) enhanced the anastrozole‐induced mechanical sensitivity in wild‐type mice, which was reduced by pre‐treatment with AZ3451. PAR2 −/− or PAR2 Na v 1.8 −/− mice treated with anastrozole did not respond to local sub‐nociceptive doses of PAR2 agonists. Conclusions and Implications: Our results provide a new mechanism underlying anastrozole‐induced pain, highlighting the mast cell/tryptase/PAR2 axis as a therapeutic target to manage painful symptoms.
- 14 December 2025
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (9) , 2009-2027
Open AccessCritical role of the mast cell/tryptase/PAR2 axis in anastrozole‐induced pain
Background and Purpose: Anastrozole, an aromatase inhibitor, is used to treat postmenopausal women with hormone receptor‐positive breast cancer, but also induces musculoskeletal pain and can lead to therapeutic regimen suspension. Aromatase inhibitors promote the release of pro‐inflammatory substances from sensitised nerve fibres, which might lead to peripheral mast cell activation. Experimental Approach: We explore if tryptase released by peripheral mast cells could activate the protease‐activated receptor 2 (PAR2) to sustain anastrozole‐induced painful symptoms. Key Results: Anastrozole caused mechanical allodynia, muscle strength loss, and increased mast cell number and tryptase levels in the plantar tissue of male C57BL/6 mice. Depletion (using compound 48/80) or stabilisation (using ketotifen fumarate) of mast cells prevented anastrozole‐induced mechanical allodynia and muscle strength loss. Compound 48/80 also prevented the increase in the number of mast cells in the plantar tissue. Tryptase inhibitors nafamostat and gabexate, or PAR2 inhibitors ENMD‐1068 and AZ3451, reduced the anastrozole‐induced mechanical allodynia and muscle strength loss. Furthermore, anastrozole did not cause mechanical allodynia and muscle strength loss in global (PAR2 −/− ) or sensory neuron‐specific (PAR2 Na v 1.8 −/− ) PAR2 knockout mice. Local sub‐nociceptive doses of the PAR2 agonists (tryptase, trypsin or 2F) enhanced the anastrozole‐induced mechanical sensitivity in wild‐type mice, which was reduced by pre‐treatment with AZ3451. PAR2 −/− or PAR2 Na v 1.8 −/− mice treated with anastrozole did not respond to local sub‐nociceptive doses of PAR2 agonists. Conclusions and Implications: Our results provide a new mechanism underlying anastrozole‐induced pain, highlighting the mast cell/tryptase/PAR2 axis as a therapeutic target to manage painful symptoms.
- Open Access
- 7 August 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8) , 1029
Repeated Administration of Guar Gum Hydrogel Containing Sesamol-Loaded Nanocapsules Reduced Skin Inflammation in Mice in an Irritant Contact Dermatitis Model
Background/Objectives: Dermatitis is frequently treated with dexamethasone cutaneous application, which causes adverse effects mainly when it is chronically administered. Sesamol is a phytochemical compound known for its anti-inflammatory activity and low toxicity. Therefore, this study reports the optimization of a guar gum hydrogel with enhanced physicochemical and microbiological stability, providing an effective dosage form for topical application of sesamol nanocapsules to treat irritant contact dermatitis. Methods: Nano-based hydrogel containing 1 mg/g sesamol was prepared by adding the nanocapsule suspension to form a 2.5% (w/v) guar gum dispersion. Dynamic rheological analysis indicates that the formulations exhibit a non-Newtonian flow with pseudoplastic behavior. Hydrogels were evaluated by Fourier-transformed infrared (FTIR) spectroscopy, and, following spectrum acquisition, an unsupervised chemometrics model was developed to identify crucial variables. Additionally, the physicochemical and microbiological stability of the hydrogel was evaluated over a 60-day period. Results: ATR-FTIR spectra of all hydrogels evaluated are very similar after preparation and 60 days of storage. However, it showed a slight increase in average diameter and PDI and decreased pH values after 60 days. Microbiological assessment demonstrated that the hydrogel met the requirements for the microbial count over 60 days. The dermatitis model was induced by repeated applications of croton oil in the right ears of mice. The effectiveness of the hydrogels was evaluated by assessing ear edema and migration of polymorphonuclear cells. The nano-based hydrogel exhibited anti-inflammatory properties similar to those of dexamethasone. Conclusions: Therefore, the nano-based hydrogel containing sesamol exhibits therapeutic potential for treating cutaneous inflammatory diseases.
- 7 August 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (8) , 1029
Open AccessRepeated Administration of Guar Gum Hydrogel Containing Sesamol-Loaded Nanocapsules Reduced Skin Inflammation in Mice in an Irritant Contact Dermatitis Model
Background/Objectives: Dermatitis is frequently treated with dexamethasone cutaneous application, which causes adverse effects mainly when it is chronically administered. Sesamol is a phytochemical compound known for its anti-inflammatory activity and low toxicity. Therefore, this study reports the optimization of a guar gum hydrogel with enhanced physicochemical and microbiological stability, providing an effective dosage form for topical application of sesamol nanocapsules to treat irritant contact dermatitis. Methods: Nano-based hydrogel containing 1 mg/g sesamol was prepared by adding the nanocapsule suspension to form a 2.5% (w/v) guar gum dispersion. Dynamic rheological analysis indicates that the formulations exhibit a non-Newtonian flow with pseudoplastic behavior. Hydrogels were evaluated by Fourier-transformed infrared (FTIR) spectroscopy, and, following spectrum acquisition, an unsupervised chemometrics model was developed to identify crucial variables. Additionally, the physicochemical and microbiological stability of the hydrogel was evaluated over a 60-day period. Results: ATR-FTIR spectra of all hydrogels evaluated are very similar after preparation and 60 days of storage. However, it showed a slight increase in average diameter and PDI and decreased pH values after 60 days. Microbiological assessment demonstrated that the hydrogel met the requirements for the microbial count over 60 days. The dermatitis model was induced by repeated applications of croton oil in the right ears of mice. The effectiveness of the hydrogels was evaluated by assessing ear edema and migration of polymorphonuclear cells. The nano-based hydrogel exhibited anti-inflammatory properties similar to those of dexamethasone. Conclusions: Therefore, the nano-based hydrogel containing sesamol exhibits therapeutic potential for treating cutaneous inflammatory diseases.
- Open Access
- 18 September 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (9) , 2116
Dual Approach to Depression: The Combined Efficacy of Intermittent Hypoxia and Fluoxetine in Modulating Behavioral and Inflammatory Responses
Background/Objectives: Mental disorders pose a significant public health challenge, affecting millions worldwide. Given the limitations of current therapies, many patients experience inadequate responses and adverse effects. Intermittent hypoxia (IH) has demonstrated anxiolytic, antidepressant, and neuroprotective properties in various protocols. This study investigated the effects of acute IH (13% O2, 1 h), fluoxetine (FLX) and their combination on depression-like behavior, serum corticosterone, and inflammatory cytokine levels induced by acute restraint stress in C57BL/6 female mice. Methods: Behavioral assessments included the tail suspension test, forced swim test, and open field test. Results: The combined IH + FLX treatment exhibited a synergistic effect, reducing immobility time and increasing latency time, respectively, in the tail suspension test (46%, p = 0.0014; 73%, p = 0.0033) and forced swim test (56%, p = 0.0082; 48%, p = 0.0322) compared to the ARS group. Biochemical analysis revealed that individual and combined treatments significantly reduced most inflammatory interleukins by up to 96%. Corticosterone levels were reduced by 30% only in the IH group. Conclusions: These findings highlight the potential of a one-hour IH session, particularly when combined with fluoxetine, to alleviate depressive-like behaviors and exert anti-inflammatory effects, suggesting a promising therapeutic approach for depression.
- 18 September 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (9) , 2116
Open AccessDual Approach to Depression: The Combined Efficacy of Intermittent Hypoxia and Fluoxetine in Modulating Behavioral and Inflammatory Responses
Background/Objectives: Mental disorders pose a significant public health challenge, affecting millions worldwide. Given the limitations of current therapies, many patients experience inadequate responses and adverse effects. Intermittent hypoxia (IH) has demonstrated anxiolytic, antidepressant, and neuroprotective properties in various protocols. This study investigated the effects of acute IH (13% O2, 1 h), fluoxetine (FLX) and their combination on depression-like behavior, serum corticosterone, and inflammatory cytokine levels induced by acute restraint stress in C57BL/6 female mice. Methods: Behavioral assessments included the tail suspension test, forced swim test, and open field test. Results: The combined IH + FLX treatment exhibited a synergistic effect, reducing immobility time and increasing latency time, respectively, in the tail suspension test (46%, p = 0.0014; 73%, p = 0.0033) and forced swim test (56%, p = 0.0082; 48%, p = 0.0322) compared to the ARS group. Biochemical analysis revealed that individual and combined treatments significantly reduced most inflammatory interleukins by up to 96%. Corticosterone levels were reduced by 30% only in the IH group. Conclusions: These findings highlight the potential of a one-hour IH session, particularly when combined with fluoxetine, to alleviate depressive-like behaviors and exert anti-inflammatory effects, suggesting a promising therapeutic approach for depression.
- 21 May 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (18) , 3445-3461
Schwann cell TRPA1 elicits reserpine‐induced fibromyalgia pain in mice
Background and Purpose: Fibromyalgia is a complex clinical disorder with an unknown aetiology, characterized by generalized pain and co‐morbid symptoms such as anxiety and depression. An imbalance of oxidants and antioxidants is proposed to play a pivotal role in the pathogenesis of fibromyalgia symptoms. However, the precise mechanisms by which oxidative stress contributes to fibromyalgia‐induced pain remain unclear. The transient receptor potential ankyrin 1 (TRPA1) channel, known as both a pain sensor and an oxidative stress sensor, has been implicated in various painful conditions.Experimental Approach: The feed‐forward mechanism that implicates reactive oxygen species (ROS) driven by TRPA1 was investigated in a reserpine‐induced fibromyalgia model in C57BL/6J mice employing pharmacological interventions and genetic approaches.Key Results: Reserpine‐treated mice developed pain‐like behaviours (mechanical/cold hypersensitivity) and early anxiety‐depressive‐like disorders, accompanied by increased levels of oxidative stress markers in the sciatic nerve tissues. These effects were not observed upon pharmacological blockade or global genetic deletion of the TRPA1 channel and macrophage depletion. Furthermore, we demonstrated that selective silencing of TRPA1 in Schwann cells reduced reserpine‐induced neuroinflammation (NADPH oxidase 1‐dependent ROS generation and macrophage increase in the sciatic nerve) and attenuated fibromyalgia‐like behaviours.Conclusion and Implications: Activated Schwann cells expressing TRPA1 promote an intracellular pathway culminating in the release of ROS and recruitment of macrophages in the mouse sciatic nerve. These cellular and molecular events sustain mechanical and cold hypersensitivity in the reserpine‐evoked fibromyalgia model. Targeting TRPA1 channels on Schwann cells could offer a novel therapeutic approach for managing fibromyalgia‐related behaviours.
- 21 May 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (18) , 3445-3461
Schwann cell TRPA1 elicits reserpine‐induced fibromyalgia pain in mice
Background and Purpose: Fibromyalgia is a complex clinical disorder with an unknown aetiology, characterized by generalized pain and co‐morbid symptoms such as anxiety and depression. An imbalance of oxidants and antioxidants is proposed to play a pivotal role in the pathogenesis of fibromyalgia symptoms. However, the precise mechanisms by which oxidative stress contributes to fibromyalgia‐induced pain remain unclear. The transient receptor potential ankyrin 1 (TRPA1) channel, known as both a pain sensor and an oxidative stress sensor, has been implicated in various painful conditions.Experimental Approach: The feed‐forward mechanism that implicates reactive oxygen species (ROS) driven by TRPA1 was investigated in a reserpine‐induced fibromyalgia model in C57BL/6J mice employing pharmacological interventions and genetic approaches.Key Results: Reserpine‐treated mice developed pain‐like behaviours (mechanical/cold hypersensitivity) and early anxiety‐depressive‐like disorders, accompanied by increased levels of oxidative stress markers in the sciatic nerve tissues. These effects were not observed upon pharmacological blockade or global genetic deletion of the TRPA1 channel and macrophage depletion. Furthermore, we demonstrated that selective silencing of TRPA1 in Schwann cells reduced reserpine‐induced neuroinflammation (NADPH oxidase 1‐dependent ROS generation and macrophage increase in the sciatic nerve) and attenuated fibromyalgia‐like behaviours.Conclusion and Implications: Activated Schwann cells expressing TRPA1 promote an intracellular pathway culminating in the release of ROS and recruitment of macrophages in the mouse sciatic nerve. These cellular and molecular events sustain mechanical and cold hypersensitivity in the reserpine‐evoked fibromyalgia model. Targeting TRPA1 channels on Schwann cells could offer a novel therapeutic approach for managing fibromyalgia‐related behaviours.
- Open Access
- 4 July 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (7) , 959
Kinin B2 Receptor Mediates Cisplatin-Induced Painful Peripheral Neuropathy by Intracellular Kinase Pathways and TRPA1 Channel Sensitisation
Chemotherapy-induced peripheral neuropathy is a severe clinical problem frequently associated with cisplatin use. Although its pathophysiology is poorly understood, it is known that kinin receptors and the transient receptor potential ankyrin 1 (TRPA1) channel play a significant role in the peripheral neuropathy induced by cisplatin in rodents. However, the role of signalling pathways downstream from B2 kinin receptors activation and sensitisation of the TRPA1 channel remains unknown in this model. The cisplatin-induced neuropathy model caused mechanical and cold allodynia in male Swiss mice. Antagonists for kinin B2 and B1 receptors and the TRPA1 channel attenuated the painful parameters. Local sub-nociceptive doses of kinin B2 receptor (bradykinin) and TRPA1 channel (allyl isothiocyanate; AITC) agonists enhanced the painful parameters in cisplatin-treated mice, which their respective antagonists attenuated. Furthermore, we demonstrated the interaction between the kinin B2 receptor and the TRPA1 channel in cisplatin-induced peripheral neuropathy since phospholipase C (PLC) and protein kinase C epsilon (PKCε) inhibitors attenuated the increase in mechanical and cold allodynia evoked by bradykinin and AITC in cisplatin-treated mice. Therefore, regulating the activation of signalling pathways downstream from the kinin B2 receptors activation and TRPA1 channel sensitisation can mitigate the painful peripheral neuropathy decurrent of the oncology treatment with cisplatin.
- 4 July 2023
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (7) , 959
Open AccessKinin B2 Receptor Mediates Cisplatin-Induced Painful Peripheral Neuropathy by Intracellular Kinase Pathways and TRPA1 Channel Sensitisation
Chemotherapy-induced peripheral neuropathy is a severe clinical problem frequently associated with cisplatin use. Although its pathophysiology is poorly understood, it is known that kinin receptors and the transient receptor potential ankyrin 1 (TRPA1) channel play a significant role in the peripheral neuropathy induced by cisplatin in rodents. However, the role of signalling pathways downstream from B2 kinin receptors activation and sensitisation of the TRPA1 channel remains unknown in this model. The cisplatin-induced neuropathy model caused mechanical and cold allodynia in male Swiss mice. Antagonists for kinin B2 and B1 receptors and the TRPA1 channel attenuated the painful parameters. Local sub-nociceptive doses of kinin B2 receptor (bradykinin) and TRPA1 channel (allyl isothiocyanate; AITC) agonists enhanced the painful parameters in cisplatin-treated mice, which their respective antagonists attenuated. Furthermore, we demonstrated the interaction between the kinin B2 receptor and the TRPA1 channel in cisplatin-induced peripheral neuropathy since phospholipase C (PLC) and protein kinase C epsilon (PKCε) inhibitors attenuated the increase in mechanical and cold allodynia evoked by bradykinin and AITC in cisplatin-treated mice. Therefore, regulating the activation of signalling pathways downstream from the kinin B2 receptors activation and TRPA1 channel sensitisation can mitigate the painful peripheral neuropathy decurrent of the oncology treatment with cisplatin.
- Open Access
- 3 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1136
Kinin B2 and B1 Receptors Activation Sensitize the TRPA1 Channel Contributing to Anastrozole-Induced Pain Symptoms
Aromatase inhibitors (AIs) cause symptoms of musculoskeletal pain, and some mechanisms have been proposed to explain them. However, signaling pathways downstream from kinin B2 (B2R) and B1 (B1R) receptor activation and their possible sensitizing of the Transient Receptor Potential Ankyrin 1 (TRPA1) remain unknown. The interaction between the kinin receptor and the TRPA1 channel in male C57BL/6 mice treated with anastrozole (an AI) was evaluated. PLC/PKC and PKA inhibitors were used to evaluate the signaling pathways downstream from B2R and B1R activation and their effect on TRPA1 sensitization. Anastrozole caused mechanical allodynia and muscle strength loss in mice. B2R (Bradykinin), B1R (DABk), or TRPA1 (AITC) agonists induced overt nociceptive behavior and enhanced and prolonged the painful parameters in anastrozole-treated mice. All painful symptoms were reduced by B2R (Icatibant), B1R (DALBk), or TRPA1 (A967079) antagonists. We observed the interaction between B2R, B1R, and the TRPA1 channel in anastrozole-induced musculoskeletal pain, which was dependent on the activation of the PLC/PKC and PKA signaling pathways. TRPA1 seems to be sensitized by mechanisms dependent on the activation of PLC/PKC, and PKA due to kinin receptors stimulation in anastrozole-treated animals. Thus, regulating this signaling pathway could contribute to alleviating AIs-related pain symptoms, patients’ adherence to therapy, and disease control.
- 3 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1136
Open AccessKinin B2 and B1 Receptors Activation Sensitize the TRPA1 Channel Contributing to Anastrozole-Induced Pain Symptoms
Aromatase inhibitors (AIs) cause symptoms of musculoskeletal pain, and some mechanisms have been proposed to explain them. However, signaling pathways downstream from kinin B2 (B2R) and B1 (B1R) receptor activation and their possible sensitizing of the Transient Receptor Potential Ankyrin 1 (TRPA1) remain unknown. The interaction between the kinin receptor and the TRPA1 channel in male C57BL/6 mice treated with anastrozole (an AI) was evaluated. PLC/PKC and PKA inhibitors were used to evaluate the signaling pathways downstream from B2R and B1R activation and their effect on TRPA1 sensitization. Anastrozole caused mechanical allodynia and muscle strength loss in mice. B2R (Bradykinin), B1R (DABk), or TRPA1 (AITC) agonists induced overt nociceptive behavior and enhanced and prolonged the painful parameters in anastrozole-treated mice. All painful symptoms were reduced by B2R (Icatibant), B1R (DALBk), or TRPA1 (A967079) antagonists. We observed the interaction between B2R, B1R, and the TRPA1 channel in anastrozole-induced musculoskeletal pain, which was dependent on the activation of the PLC/PKC and PKA signaling pathways. TRPA1 seems to be sensitized by mechanisms dependent on the activation of PLC/PKC, and PKA due to kinin receptors stimulation in anastrozole-treated animals. Thus, regulating this signaling pathway could contribute to alleviating AIs-related pain symptoms, patients’ adherence to therapy, and disease control.
- 12 April 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 293, 115291
Stephalagine, an aporphinic alkaloid with therapeutic effects in acute gout arthritis in mice
- 12 April 2022
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 293, 115291
Stephalagine, an aporphinic alkaloid with therapeutic effects in acute gout arthritis in mice
- Open Access
- 16 March 2022
- Published by Elsevier in SSRN Electronic Journal
Stephalagine, an Aporphinic Alkaloid with Therapeutic Effects in Acute Gout Arthritis in Mice
Ethnopharmacological relevance: Gout is an inflammatory disease characterized by the accumulation of monosodium urate (MSU) crystals in the joints, leading to severe pain and inflammation. Natural products are an important source for drug discoveries, and many alkaloids isolated from these products, such as stephalagine, have been described with antinociceptive properties. Stephalagine is a Brazilian Savanna aporphine alkaloid isolated from Annona crassiflora Mart. fruit peel, which has been popularly used to treat rheumatism. However, no studies evaluated the possible therapeutic properties of stephalagine in arthritic pain. Aim of the study: To investigate the possible antinociceptive and anti-inflammatory effects of stephalagine in an acute gout attack in mice. Materials and methods: Adult male wild-type C57BL/6/J/UFU mice (20–25 g) were used (ethical approval number 018/17). The treated group received stephalagine by oral route (0,3-1 mg/kg, gavage) and the vehicle group received saline (10 mL/kg, gavage), both 1 hour before the MSU crystals (100 µg/ankle joint) administration. All groups were analyzed for mechanical allodynia, thermal hyperalgesia, overt pain-like behaviors, and edema development at 2, 4, 6, and 24 h after injections. Synovial fluid and the ankle articulation from the injected joint were collected at 4 h after administrations for myeloperoxidase enzyme activity, IL-1β measurement, and histological analysis. Results: The stephalagine (1 mg/kg) had a significant antinociceptive effect (P<0.05–0.01) on mechanical allodynia, when compared to vehicle group at 2, 4, 6, and 24 h after intra-articular injection of MSU and, at 2 h for spontaneous and cold thermal sensitivity. Stephalagine (1 mg/kg) was also able to significantly reduce the articular edema (45 ± 1%), the activity of the myeloperoxidase enzyme (37 ± 6%), and the IL-1β levels (43 ± 3%) in the joint tissues of the mice when compared to vehicle group. The histological analysis confirms that stephalagine dramatically reduced the number of infiltrating inflammatory cells (75 ± 6%) in MSU injected animals. The stephalagine treatment did not alter the uric acid levels, xanthine oxidase activity, or AST and ALT activities, urea or creatinine levels. It was also observed, for 7 days, that stephalagine did not cause any macroscopic changes in the mice’s weight, deformations, changes in the coat, or feces. Conclusion: Stephalagine may be an alternative for the management of gout, once it was able to induce antinociceptive and anti-inflammatory effects without causing adverse effects on the evaluated parameters.
- 16 March 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessStephalagine, an Aporphinic Alkaloid with Therapeutic Effects in Acute Gout Arthritis in Mice
Ethnopharmacological relevance: Gout is an inflammatory disease characterized by the accumulation of monosodium urate (MSU) crystals in the joints, leading to severe pain and inflammation. Natural products are an important source for drug discoveries, and many alkaloids isolated from these products, such as stephalagine, have been described with antinociceptive properties. Stephalagine is a Brazilian Savanna aporphine alkaloid isolated from Annona crassiflora Mart. fruit peel, which has been popularly used to treat rheumatism. However, no studies evaluated the possible therapeutic properties of stephalagine in arthritic pain. Aim of the study: To investigate the possible antinociceptive and anti-inflammatory effects of stephalagine in an acute gout attack in mice. Materials and methods: Adult male wild-type C57BL/6/J/UFU mice (20–25 g) were used (ethical approval number 018/17). The treated group received stephalagine by oral route (0,3-1 mg/kg, gavage) and the vehicle group received saline (10 mL/kg, gavage), both 1 hour before the MSU crystals (100 µg/ankle joint) administration. All groups were analyzed for mechanical allodynia, thermal hyperalgesia, overt pain-like behaviors, and edema development at 2, 4, 6, and 24 h after injections. Synovial fluid and the ankle articulation from the injected joint were collected at 4 h after administrations for myeloperoxidase enzyme activity, IL-1β measurement, and histological analysis. Results: The stephalagine (1 mg/kg) had a significant antinociceptive effect (P<0.05–0.01) on mechanical allodynia, when compared to vehicle group at 2, 4, 6, and 24 h after intra-articular injection of MSU and, at 2 h for spontaneous and cold thermal sensitivity. Stephalagine (1 mg/kg) was also able to significantly reduce the articular edema (45 ± 1%), the activity of the myeloperoxidase enzyme (37 ± 6%), and the IL-1β levels (43 ± 3%) in the joint tissues of the mice when compared to vehicle group. The histological analysis confirms that stephalagine dramatically reduced the number of infiltrating inflammatory cells (75 ± 6%) in MSU injected animals. The stephalagine treatment did not alter the uric acid levels, xanthine oxidase activity, or AST and ALT activities, urea or creatinine levels. It was also observed, for 7 days, that stephalagine did not cause any macroscopic changes in the mice’s weight, deformations, changes in the coat, or feces. Conclusion: Stephalagine may be an alternative for the management of gout, once it was able to induce antinociceptive and anti-inflammatory effects without causing adverse effects on the evaluated parameters.